SCHEMBL2593687

SCHEMBL2593687

Clc1nccnc1C1CN(c2ncc3ccccc3n2)C1

nearest known ligand 0.71

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 20/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2593893 0.83 PDE10A (1.00) PDE10A
SCHEMBL2595732 0.83 PDE10A (1.00) PDE10A
SCHEMBL2595899 0.81 PDE10A (1.00) PDE10A
SCHEMBL2595694 0.80 PDE10A (0.69) PDE10A
SCHEMBL7707446 0.80 PDE10A (0.62) PDE10A
SCHEMBL2593667 0.78 PDE10A (1.00) PDE10A
SCHEMBL2595757 0.78 PDE10A (1.00) PDE10A
SCHEMBL7708217 0.77 HTR3A (0.58) PDE10A
SCHEMBL2595691 0.76 PDE10A (1.00) PDE10A
SCHEMBL2593907 0.76 PDE10A (0.75) PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9718803-B2 Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors AMGEN INC. (US) 2017-08-01 US disclosed
US-9718803-B2 Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors AMGEN INC. (US) 2017-08-01 US disclosed
US-9718803-B2 Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors AMGEN INC. (US) 2017-08-01 US disclosed
US-9493459-B2 Azetidine and piperidine compounds useful as PDE10 inhibitors AMGEN INC. (US) 2016-11-15 US disclosed
US-9493459-B2 Azetidine and piperidine compounds useful as PDE10 inhibitors AMGEN INC. (US) 2016-11-15 US disclosed
US-9493459-B2 Azetidine and piperidine compounds useful as PDE10 inhibitors AMGEN INC. (US) 2016-11-15 US disclosed
US-20160176874-A1 AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS AMGEN INC. 2016-06-23 US disclosed
US-20160176874-A1 AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS AMGEN INC. 2016-06-23 US disclosed
US-20160176874-A1 AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS AMGEN INC. 2016-06-23 US disclosed
US-20160102075-A1 UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS AMGEN INC. (US) 2016-04-14 US disclosed
US-8691986-B2 Azetidine and piperidine compounds useful as PDE10 inhibitors AMGEN INC. (US) 2014-04-08 US disclosed
US-8691986-B2 Azetidine and piperidine compounds useful as PDE10 inhibitors AMGEN INC. (US) 2014-04-08 US disclosed
US-20130338138-A1 AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS AMGEN INC. 2013-12-19 US disclosed
CN-103221404-A Nitrogen heterocyclic compounds useful as PDE10 inhibitors AMGEN INC 2013-07-24 CN disclosed
EP-2569300-A1 NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS Amgen Inc. (US) 2013-03-20 EP disclosed
US-20110306587-A1 UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS AMGEN INC. 2011-12-15 US disclosed
US-20110306587-A1 UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS AMGEN INC. 2011-12-15 US disclosed
US-20110306587-A1 UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS AMGEN INC. 2011-12-15 US disclosed
WO-2011143365-A1 NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS AMGEN INC. (US) 2011-11-17 WO disclosed
WO-2011143365-A1 NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS AMGEN INC. (US) 2011-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160176874-A1 AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS PDE10A, PDE9A, PDE2A PDE10A 1/4885
US-20130338138-A1 AZETIDINE AND PIPERIDINE COMPOUNDS USEFUL AS PDE10 INHIBITORS PDE10A, PDE9A, PDE2A PDE10A 1/4885
US-20160102075-A1 UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS PDE10A, PDE2A, PDE3A PDE10A 1/4885
US-20110306587-A1 UNSATURATED NITROGEN HETEROCYCLIC COMPOUNDS USEFUL AS PDE10 INHIBITORS PDE10A, PDE2A, PDE3A PDE10A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.